Cancer drug trade margins to be capped at 30% of retail price
The price regulator has approved in principle a 30% cap on trade margins for 110 expensive cancer medicines that currently sit outside price control, where average mark-ups run about 170% and reach 700%. Retail prices are expected to fall 20-70%, saving patients roughly ₹2,500 crore a year.
What happened
The Union government decided to cap trade margins on 110 expensive cancer medicines, including around 35 patented ones, covering branded, generic, domestically manufactured and imported versions. The National Pharmaceutical Pricing Authority's minutes record that it "approved, in principle, the proposal for Trade Margin Rationalization of identified non-scheduled anti-cancer drugs under Paragraph 19 of DPCO, 2013, by capping the trade margin at 30% of MRP subject to finalization of the list". The list is being finalised by the Director General of Health Services, and officials expect marked prices to fall by up to 70%.
Context
A trade margin is the gap between the price at which a medicine is sold to a stockist — the first point of sale — and its maximum retail price, and that gap can run as high as 1,000% of the first-point cost. The drugs covered are not scheduled, meaning they are not on the National List of Essential Medicines and so are not under price control; the only existing restraint is that their retail price cannot rise more than 10% a year. The approach follows a 2019 pilot on 42 cancer medicines, including chemotherapy drugs such as Cytarabine and Mitoxantrone and immunotherapy drugs such as osimertinib for lung cancer and ribociclib for breast cancer, which cut maximum retail prices by up to 91% and saved approximately ₹984 crore a year.
Why it matters
Capping a margin is a different instrument from capping a price, and the choice matters. For scheduled drugs the government fixes a ceiling price from the average market price of the most commonly selling brands, which requires doing that calculation for every formulation, dose and brand. Trade margin rationalisation instead caps the permitted mark-up, so one rule covers the whole set — a 30% cap means a medicine sold to a stockist at ₹70 can carry a retail price of only ₹100. That is administratively lighter, and it is why the instrument reaches 110 drugs at once. The reason it is being reached for is access rather than price as such: a real-world study from Tata Memorial Hospital found that only 1.6% of patients who need targeted and immunotherapy drugs are able to get them, with cost among the most significant barriers. The scale of the untouched segment explains the headroom — annual cancer drug turnover is around ₹12,500 crore, of which scheduled drugs whose prices are regulated account for only about ₹2,250 crore. The limitation is at the other end of the chain. Because nothing controls the price to the stockist, an expert quoted in the reporting described how a company could sell 1,000 vials at an inflated price and supply 500 free, keeping prices artificially high while formally observing the 30% cap.
Impact for India
- Patients: retail prices expected to fall broadly in the range of 20-70%, with annual savings of approximately ₹2,500 crore.
- Market coverage: 110 medicines including around 35 patented ones, covering branded, generic, domestic and imported versions, against a cancer drug market of about ₹12,500 crore of which only around ₹2,250 crore is currently price-regulated.
- Distributors and stockists: average mark-ups on non-scheduled anti-cancer drugs run about 170% and reach up to 700% in some cases; a 30% cap compresses that sharply.
- Cheaper drugs deliberately excluded: an official said a 30% cap on inexpensive drugs can disincentivise companies because it does not cover marketing costs, so expensiveness is itself a selection criterion.
- The gaming risk: with no control over the price to stockist, free-goods arrangements can keep effective prices high while the margin cap is formally met.
Key data
Concepts
Theory lens
Double marginalisation in a vertical chain — when a manufacturer and a distributor each add a mark-up independently, the final price exceeds what a single integrated firm would charge, and the loss falls on the consumer. Capping the downstream margin at 30% attacks the second mark-up directly. The limitation is the standard one: regulating only one stage gives the parties an incentive to move the margin upstream, which is exactly the free-goods arrangement the experts quoted describe.
Historical parallel
The 2019 pilot on 42 cancer medicines is the direct precedent and the basis for the mechanism being used again. It reduced maximum retail prices by up to 91% and produced annual savings of approximately ₹984 crore, on a much smaller list. The present exercise applies the same formula to 110 drugs for an expected saving of about ₹2,500 crore, so the earlier round is both the proof of concept and the reason the regulator expects the effect to hold.
Stakeholders
Practice Question — from the story
With reference to trade margin rationalisation for cancer medicines, consider the following statements:
- The price regulator approved capping the trade margin at 30% of the maximum retail price for identified non-scheduled anti-cancer drugs.
- The drugs covered are scheduled medicines on the National List of Essential Medicines whose ceiling prices are already fixed.
Which of the statements given above is/are correct?
Reveal answer & explanation
Answer: 1 only
- Statement 1: Correct — the Authority approved in principle a 30% cap on the trade margin of identified non-scheduled anti-cancer drugs under Paragraph 19 of DPCO, 2013.
- Statement 2: Incorrect because the drugs are specifically non-scheduled and therefore not under price control; the only existing restraint on them is that their retail price cannot rise more than 10% a year.
Therefore, the correct answer is 1 only.
Concept check — test your understanding
Why might capping a trade margin be preferred to fixing a ceiling price for a large set of medicines?
Reveal answer & explanation
Answer: C
- Ceiling-price fixation requires calculating an average market price for each formulation and brand. A single 30% cap on the mark-up scales across the whole list at once, which is how 110 drugs could be covered in one decision.
- Option A is precisely what a margin cap does not do, and is the gap the experts quoted identify as gameable through free-goods arrangements.
- Option B overstates the instrument; the expected reduction here is a range, and a ceiling price could in principle cut more.
- Option D is a plausible-sounding distinction, and around 35 patented drugs are on this list — but what makes them eligible is being non-scheduled, not being patented.